可注射凝多重乳液,用于提供对葡萄糖敏感的胰岛素
Kofi Oti Boakye-Yiadom1,2, Qijing Chen1,2, Yilong Teng1,2
1Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Advanced healthcare materials
|July 12, 2024
概括
这项研究介绍了一种使用凝多重乳液的新型葡萄糖反应性胰岛素输送系统. 这个系统有效地控制糖尿病小鼠的血糖水平,长时间.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 糖尿病研究 糖尿病研究
背景情况:
- 糖尿病的胰岛素治疗受到狭窄的治疗窗口的限制.
- 发展葡萄糖反应系统对于持续的血糖控制至关重要.
研究的目的:
- 开发一种使用凝多重乳液的新型葡萄糖反应性胰岛素输送系统.
- 在1型糖尿病小鼠模型中评估其疗效.
主要方法:
- 胰岛素被装入水中的油中的水 (W1/O/W2) 凝多重乳液中,该乳液由聚4-乙烯基酸 (PVPBA) 稳定.
- 评估了系统的封装效率,稳定性和可注射性.
- 在实验室中研究了由葡萄糖触发的胰岛素释放.
- 在体内有效性被评估在链毒素诱导的1型糖尿病小鼠中.
主要成果:
- 凝乳液实现了99%的封装效率,增强了稳定性和剪切稀释性能,方便注射.
- 该系统在高血糖条件下证明了依赖葡萄糖的胰岛素释放.
- 对糖尿病小鼠进行一次皮下注射,与免费胰岛素相比,显示出长时间的抗高血糖作用.
结论:
- 开发的凝多重乳液作为一种有效的葡萄糖反应性胰岛素输送系统.
- 该系统提供持续的血糖平衡,解决传统胰岛素治疗的局限性.
- 基于PVPBA的乳液显示了改善糖尿病管理的前景.
更多相关视频
相关概念视频
Insulin Formulations: Types and Delivery
184
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
184
Glucagon-like Receptor Agonists
313
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
313
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Insulin: Dosing Regimen and Adverse Effects
165
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
165
Insulin Secretory Vesicles
4.9K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.9K
Insulin: Biosynthesis, Chemistry, and Preparation
370
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
370


